BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Drones haven't won the fight in Ukraine. That matters as the West learns new ways of war. - 2Survey: Canteen Cups With Great Warm Protection Impact
- 3Concern for couple jailed in Tehran as British embassy closes
- 4Building an Individual Brand: Illustrations from Forces to be reckoned with
- 5The most effective method to Connect Successfully with Teachers in a Web based Setting
- Instructions to Keep up with Your Traded Teeth for Life span
- Improving as a Cook: Culinary Experiences in the Kitchen
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- The Best Web-based Courses for Ability Advancement
- SUVs Known for Their Looks As opposed to Their Capacity
- 6 Famous Cell phone Brands All over The Planet
- 7 Methods for further developing Rest Quality
- Meet ‘NASA Mike,’ who’s done 105,000 handstands around the world
